Phase 1 Study to Evaluate Safety, Tolerability, PK, and PK Interactions of TBA-7371

Submitted by barbara on

The primary objective of the study was to evaluate the safety and tolerability of single and multiple doses of TBA-7371 in healthy subjects.

The trial completed in July 2018, with no results published since. TBA-7371 has since been tested in a Phase 2a study (https://clinicaltrials.gov/study/NCT04176250).

Phase 2 Telacebec (Q203) EBA

Submitted by barbara on

This is a Phase IIa, open-label, randomized study in treatment-naïve, sputum smear-positive patients with drug-sensitive pulmonary TB to assess the early bactericidal activity of telacebec (Q203).  Posted to clinicaltrials.gov June 21, 2018  NCT03563599  As of March 19, 2019, enrollment complete.

Primary Outcome Measures :

What is Needed to End TB and Who TB Most Affects

Bloomberg News reported this week on how world leaders can be successful in ending TB by 2030 and the demographics that TB affects most. One article discusses multi-drug and extensive drug resistant patients as well as challenges, funding needs, and the needs for new tools to defeat TB. The other discusses TB's strong link to the most impovershed populations. To read more, please click below: 

SimpliciTB-Pa-M-Z) NC-008

Submitted by barbara on

To evaluate the efficacy, safety and tolerability at 8 weeks (2-months), 52 weeks (12-months), and 104 Weeks (24-months) post the start of the following treatment regimens in participants with: Drug Sensitive TB (DS-TB) patients given BPaMZ for 17 Weeks ( or 4 months) vs. Standard HRZE/HR treatment given for 26 weeks (or 6 months) and Drug Resistant TB (DR-TB) patients given BPaMZ for 26 Weeks (or 6 months)

TB Drug Accelerator

Submitted by barbara on

The TBDA is a novel collaboration of 17 research organizations with the goal of discovering multiple mechanistically distinct TB candidates sufficient to advance a drug regimen to a 1 month POC by 2024.  The TBDA is a groundbreaking partnership between: 8 Pharmaceutical companies (Abbvie, GSK, Lilly, Merck, Eisai, Bayer, AstraZeneca, Sanofi),  5 Major Universities (Cornell, Texas A&M, Colorado State, University of Cape Town, and University of Dundee), 2 Research Institutes (IDRI and Calibr), 1 National Institute (NIAID),1 non profit PDP (TB Alliance).

GSK-286

Submitted by barbara on

2025. Phase 1 terminated per stopping rules. 92/96 enrolled.

 

2023. Brown KL, Wilburn KM, Montague CR, Grigg JC, Sanz O, Pérez-Herrán E, Barros D, Ballell L, VanderVen BC, Eltis LD. 

Cyclic AMP-Mediated Inhibition of Cholesterol Catabolism in Mycobacterium tuberculosis by the Novel Drug Candidate GSK2556286. Antimicrob Agents Chemother. 2023 Jan 24;67(1):e0129422. doi: 10.1128/aac.01294-22. Epub 2023 Jan 5. PMID: 36602336; PMCID: PMC9872607.

Pages

Subscribe to Working Group for New TB Drugs RSS